Future studies employing integrated multi-omics and spatial analyses will be crucial to confirm these mechanisms, define causal pathways, and harness the full therapeutic potential of SGLT2 inhibition in kidney disease. This evidence concerns the gene SLC5A2 and kidney disorder.